PROPOSED mRNA CANCER PROGRAM
& VACCINE DEVELOPMENT FOR TARGETS
Status: Program paused due to pandemic. Anticipate restarting the program in early 2022.
Strategy: Personalized vaccine design based on information from the patient's own tumour.
Designed to generate strong T-cell responses that aim to kill cancer cells and destroy tumours.
Learn the inspiring story behind Providence Therapeutics and the technology that makes it all possible by watching the video below.
Providence’s lead personalized mRNA cancer vaccine will treat women with advanced ovarian cancer before expanding into other cancers including brain and breast cancer. This trial will be an open-label, dose-escalation, safety study. Primary endpoints will be safety, tolerance, and pharmacodynamics. Secondary endpoints will include objective response, time to progression, and immune response. The study will be led by Dr. Amit Oza in Toronto.
In addition to PTX-101, Providence is currently working on next-generation mRNA cancer vaccines based on novel ideas generated by our scientific advisory board. These projects are in the discovery phase. Providence plans to bring them to the clinic as soon as possible to help change and improve the standard of care in multiple cancer types.
We are part of the mRNA Revolution.